New pill aims to fight daytime sleepiness and sudden muscle collapse

NCT ID NCT07455383

Recruiting now Symptom relief Sponsor: Alkermes, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 4 times

Summary

This phase 3 trial tests whether a daily tablet called ALKS 2680 can reduce daytime sleepiness and cataplexy (sudden muscle weakness) in 150 adults with narcolepsy type 1. Participants will take the drug or a placebo for 12 weeks, and researchers will measure changes in sleep tests and symptom reports.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ALKS 2680 (alixorexton) tablets
What this could lead to: If successful, this could provide a new daily medication to better control sleepiness and sudden muscle weakness in people with narcolepsy type 1.
What could go wrong: This is still an experimental drug; it may not work better than a placebo, and side effects are possible. The trial is relatively small (150 people) and lasts only 12 weeks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cataplexy Disorders of Excessive Somnolence Fatigue narcolepsy narcolepsy-cataplexy syndrome sleep-wake disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NARCOLEPSY TYPE 1

Contacts and locations

Locations

Alkermes Investigational Site
RECRUITING

Cullman, Alabama, 35055, United States
Alkermes Investigational Site
RECRUITING

Phoenix, Arizona, 85054, United States
Alkermes Investigational Site
RECRUITING

Los Angeles, California, 90025, United States
Alkermes Investigational Site
RECRUITING

Boulder, Colorado, 80301, United States
Alkermes Investigational Site
RECRUITING

Brandon, Florida, 33511, United States
Alkermes Investigational Site
RECRUITING

Miami, Florida, 33176, United States
Alkermes Investigational Site
RECRUITING

Winter Park, Florida, 32789, United States
Alkermes Investigational Site
RECRUITING

Macon, Georgia, 31210, United States
Alkermes Investigational Site
RECRUITING

Kansas City, Kansas, 66160, United States
Alkermes Investigational Site
RECRUITING

Newton, Massachusetts, 02459, United States
Alkermes Investigational Site
RECRUITING

Lansing, Michigan, 48911, United States
Alkermes Investigational Site
RECRUITING

St Louis, Missouri, 63123, United States
Alkermes Investigational Site
RECRUITING

Middletown, New Jersey, 07748, United States
Alkermes Investigational Site
RECRUITING

Charlotte, North Carolina, 28210, United States
Alkermes Investigational Site
RECRUITING

Cincinnati, Ohio, 45245, United States
Alkermes Investigational Site
RECRUITING

Wyomissing, Pennsylvania, 19610, United States
Alkermes Investigational Site
RECRUITING

Columbia, South Carolina, 29201, United States
Alkermes Investigational Site
RECRUITING

Austin, Texas, 78731, United States
Alkermes Investigational Site
RECRUITING

San Antonio, Texas, 78229, United States
Alkermes Investigational Site
RECRUITING

Sugar Land, Texas, 77478, United States
Alkermes Investigational Site
RECRUITING

Macquarie Park, New South Wales, 2113, Australia
Alkermes Investigational Site
RECRUITING

Namur, Belgium
Alkermes Investigational Site
RECRUITING

Markham, Ontario, L3R 1A3, Canada
Alkermes Investigational Site
RECRUITING

Toronto, Ontario, M5S 3A3, Canada
Alkermes Investigational Site
RECRUITING

Bordeaux, France
Alkermes Investigational Site
RECRUITING

Lyon, France
Alkermes Investigational Site
RECRUITING

Montpellier, France
Alkermes Investigational Site
RECRUITING

Zwolle, Overijssel, 8011, Netherlands
Alkermes Investigational Site
RECRUITING

Heeze, 5591 VE, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.